{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:29:09Z","timestamp":1777530549347,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1007\/s11914-004-0011-5","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T18:47:20Z","timestamp":1180118840000},"page":"24-30","source":"Crossref","is-referenced-by-count":7,"title":["Intravenous bisphosphonate therapy for osteoporosis: Where do we stand?"],"prefix":"10.1007","volume":"2","author":[{"given":"Henry G.","family":"Bone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Schurr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"11_CR1","volume-title":"Bisphosphonates in Bone Disease: from the Laboratory to the Patient","author":"H Fleisch","year":"2000","unstructured":"Fleisch H: Bisphosphonates in Bone Disease: from the Laboratory to the Patient. San Diego: Academic Press; 2000. This is a comprehensive and masterful monograph by one of the great figures in the bisphosphonate field."},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-003-0085-6","volume":"5","author":"AA Rezka","year":"2003","unstructured":"Rezka AA, Rodan GA: Bisphosphonate mechanism of action.Curr Rheumatol Rep 2003, 5:65\u201374.","journal-title":"Curr Rheumatol Rep"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-199936050-00002","volume":"36","author":"AG Porras","year":"1999","unstructured":"Porras AG, Holland SD, Gertz BJ:Pharmacokinetics of alendronate. Clin Pharmacol 1999, 36:315\u2013328.","journal-title":"Clin Pharmacol"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","volume":"104","author":"LI Plotkin","year":"1999","unstructured":"Plotkin LI, Weinstein RS, Parfitt AM, et al.:Prevention of osteocytes and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999, 104:1363\u20131374.","journal-title":"J Clin Invest"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Wells G, Willan A, et al.:Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002, 23:508\u2013516.","journal-title":"Endocr Rev"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Tugwell P, Adachi J, et al.:Meta-analyses of therapies for postmenopausal osteoporosis. III. Metaanalysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:517\u2013523.","journal-title":"Endocr Rev"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"A Cranney","year":"2002","unstructured":"Cranney A, Guyatt G, Griffith L, et al.:Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002, 23:570\u2013578.","journal-title":"Endocr Rev"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jcem.87.4.8415","volume":"87","author":"MC Hochberg","year":"2002","unstructured":"Hochberg MC, Greenspan S, Wasnich RD, et al.:Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87:1586\u20131592.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR9","unstructured":"Bone H, Hosking D, Devogelaer JP, et al.: For the Alendronate Phase III Osteoporosis Treatment Study Group; ten year experience with alendronate in the treatment of postmenopausal osteoporotic women. N Engl J Med, In press."},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","volume":"11","author":"P Garnero","year":"1996","unstructured":"Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD:Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996, 11:337\u2013349.","journal-title":"J Bone Miner Res"},{"key":"11_CR11","first-page":"1","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, et al.:Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000, 12:1\u201312.","journal-title":"Aging (Milano)"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","volume":"71","author":"JP Brown","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR, et al.:The efficacy and tolerability of risedronate once a week for treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71:103\u2013111.","journal-title":"Calcif Tissue Int"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00198-003-1409-0","volume":"14","author":"C Christiansen","year":"2003","unstructured":"Christiansen C, Tanko LB, Warming L, et al.:Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int 2003, 14:609\u2013613.","journal-title":"Osteoporos Int"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S8756-3282(00)00325-2","volume":"27","author":"RD Chapurlat","year":"2000","unstructured":"Chapurlat RD, Garnero P, Breart G, et al.:Serum type I collagen breakdown product (serum CTx) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000, 27:283\u2013286.","journal-title":"Bone"},{"issue":"Suppl 2","key":"11_CR15","first-page":"5209","volume":"11","author":"RR Recker","year":"2000","unstructured":"Recker RR, Stakkestad JA, Felsenberg D, et al.:A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial [abstract 565]. Osteoporos Int 2000, 11(Suppl 2):5209.","journal-title":"Osteoporos Int"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1517\/14656566.4.3.391","volume":"4","author":"RD Chapurlat","year":"2003","unstructured":"Chapurlat RD, Delmas PD: Review of ibandronate in the treatment of osteoporosis. Expert Opin Pharmacother 2003, 4:391\u2013396.","journal-title":"Expert Opin Pharmacother"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-003-0016-9","volume":"4","author":"A Lipton","year":"2003","unstructured":"Lipton A: Bone metastases in breast cancer. Curr Treat Options Oncol 2003, 4:15\u201318.","journal-title":"Curr Treat Options Oncol"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11912-003-0117-4","volume":"5","author":"MD Michaelson","year":"2003","unstructured":"Michaelson MD, Smith MR: The role of bisphosphonates in the management of metastatic prostate cancer. Curr Oncol Rep 2003, 5:245\u2013249.","journal-title":"Curr Oncol Rep"},{"issue":"Suppl 1","key":"11_CR19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000072485","volume":"65","author":"A Heidenreich","year":"2003","unstructured":"Heidenreich A: Bisphosphonates in the management of metastatic prostate cancer. Oncology 2003, 65(Suppl 1):5\u201311.","journal-title":"Oncology"},{"issue":"Suppl 16","key":"11_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.seminoncol.2003.08.018","volume":"30","author":"GN Hortobagyi","year":"2003","unstructured":"Hortobagyi GN: Novel approaches to the management of bone metastases. Semin Oncol 2003, 30(Suppl 16):161\u2013166.","journal-title":"Semin Oncol"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1468-0734.2002.00077.x","volume":"6","author":"JL Harousseau","year":"2002","unstructured":"Harousseau JL: Management of multiple myeloma. Rev Clin Exp Hematol 2002, 6:253\u2013275.","journal-title":"Rev Clin Exp Hematol"},{"issue":"Suppl 2","key":"11_CR22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CNV-120014886","volume":"20","author":"A Lipton","year":"2002","unstructured":"Lipton A, Small E, Saad F, et al.:The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002, 20(Suppl 2):45\u201354.","journal-title":"Cancer Invest"},{"issue":"Suppl 12","key":"11_CR23","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/1097-0142(20000615)88:12+<3054::AID-CNCR23>3.0.CO;2-Z","volume":"15","author":"JJ Body","year":"2000","unstructured":"Body JJ: Current and future directions in medical therapy: hypercalcemia. Cancer 2000, 15(Suppl 12):3054\u20133058.","journal-title":"Cancer"},{"key":"11_CR24","first-page":"1595","volume":"79","author":"IR Reid","year":"1994","unstructured":"Reid IR, Wattie DJ, Evans MC, et al.:Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994, 79:1595\u20131599.","journal-title":"J Clin Endocrinol Metab"},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","volume":"17","author":"C Brumsen","year":"2002","unstructured":"Brumsen C, Papapoulos S, Lips P, et al.:Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002, 17:1057\u20131064.","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"11_CR26","first-page":"S15","volume":"13","author":"PD Delmas","year":"2002","unstructured":"Delmas PD, Recker, RR, Stakkestad JA, et al.: Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: results from a pivotal phase III study [abstract 037]. Osteoporos Int 2002 13(Suppl 1):S15.","journal-title":"Osteoporos Int"},{"key":"11_CR27","first-page":"175","volume":"45","author":"CE Machado","year":"1996","unstructured":"Machado CE, Flombaum CD: Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 1996, 45:175\u2013179.","journal-title":"Clin Nephrol"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1016\/S0272-6386(03)00214-2","volume":"41","author":"D Banerjee","year":"2003","unstructured":"Banerjee D, Asif A, Striker L, et al.:Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003, 41:E18.","journal-title":"Am J Kidney Dis"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/01926233900184P204","volume":"18","author":"CL Alden","year":"1990","unstructured":"Alden CL, Burns JL, Parker RD, et al.:Characterization of the early ultrastructural and biochemical events occurring in dichloromethane diphosphonate nephrotoxicity. Toxicol Pathol 1990, 18:661\u2013666.","journal-title":"Toxicol Pathol"},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowtiz","year":"2003","unstructured":"Markowtiz GS, Fine PL, Stack JI, et al.:Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003, 64:281\u2013289.","journal-title":"Kidney Int"},{"key":"11_CR31","first-page":"1676","volume":"347","author":"JT Chang","year":"2003","unstructured":"Chang JT, Green L, Beitz J: Renal failure with the use of zoledronic acid. N Engl J Med 2003, 347:1676\u20131678.","journal-title":"N Engl J Med"},{"key":"11_CR32","first-page":"1678","volume":"347","author":"P Tarassoff","year":"2003","unstructured":"Tarassoff P, Hei YJ, Maladorno D: Renal failure with the use of zoledronic acid. N Engl J Med 2003, 347:1678\u20131679.","journal-title":"N Engl J Med"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF01623227","volume":"4","author":"D Thiebaud","year":"1994","unstructured":"Thiebaud D, Burckhardt P, Melchior J, et al.:Two years\u2019 effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994, 4:76\u201383.","journal-title":"Osteoporos Int"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0378-5122(96)01118-8","volume":"25","author":"A Peretz","year":"1996","unstructured":"Peretz A, Body JJ, Dumon JC, et al.:Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996, 25:69\u201375.","journal-title":"Maturitas"},{"key":"11_CR35","first-page":"446","volume":"58","author":"M Sarli","year":"1998","unstructured":"Sarli M, Fradinger E, Morillo S, et al.:Treatment of post menopausal osteoporosis with intravenous pamidronate in patients with esophagogastric pathology [in Spanish]. Medicina 1998, 58:446\u2013452.","journal-title":"Medicina"},{"key":"11_CR36","first-page":"2057","volume":"88","author":"G Guttmann","year":"1999","unstructured":"Guttmann G, Van Linthoudt D: Efficacy of intravenous pamidronate in osteoporosis, mineralometric evaluation [in French]. Schweiz Rundsch Med Prax 1999 88:2057\u20132060.","journal-title":"Schweiz Rundsch Med Prax"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00223001126","volume":"67","author":"T Bianda","year":"2002","unstructured":"Bianda T, Linka A, Junga G, Brunner H, et al.:Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 2002, 67:116\u2013121.","journal-title":"Calcif Tissue Int"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","volume":"16","author":"Y Boutsen","year":"2001","unstructured":"Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP: Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001, 16:104\u2013112.","journal-title":"J Bone Miner Res"},{"key":"11_CR39","first-page":"5276","volume":"14","author":"F Caldeari","year":"1999","unstructured":"Caldeari F, Burckhardt P: Treatment of osteoporosis with intravenous pamidronate: a retrospective analysis [abstract F336]. J Bone Miner Res 1999 14:5276.","journal-title":"J Bone Miner Res"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/lt.500040508","volume":"4","author":"HL Reeves","year":"1998","unstructured":"Reeves HL, Francis RM, Manas DM, et al.:Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 1998, 4:404\u2013409.","journal-title":"Liver Transpl Surg"},{"key":"11_CR41","first-page":"1089","volume":"17","author":"E Shane","year":"1998","unstructured":"Shane E, Rodino MA, McMahon DJ, et al.:Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 1998 17:1089\u20131096.","journal-title":"J Heart Lung Transplant"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1164\/ajrccm.162.3.2002051","volume":"162","author":"RM Aris","year":"2000","unstructured":"Aris RM, Lester GE, Renner JB, et al.:Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 2000, 162:941\u2013946.","journal-title":"Am J Respir Crit Care Med"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s001980170142","volume":"12","author":"MA Krieg","year":"2001","unstructured":"Krieg MA, Seydoux C, Sandini L, et al.:Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 2001, 12:112\u2013116.","journal-title":"Osteoporos Int"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00198-002-1315-x","volume":"14","author":"P Dodidou","year":"2003","unstructured":"Dodidou P, Bruckner T, Hosch S, et al.:Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 2003, 14:82\u201389.","journal-title":"Osteoporos Int"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","volume":"92","author":"TH Diamond","year":"2001","unstructured":"Diamond TH, Winters J, Smith A, et al.:The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001, 92:1444\u20131450.","journal-title":"Cancer"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/cncr.11149","volume":"97","author":"MR Smith","year":"2003","unstructured":"Smith MR: Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 2003, 97:789\u2013795.","journal-title":"Cancer"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/adc.83.2.143","volume":"83","author":"NJ Shaw","year":"2000","unstructured":"Shaw NJ, Boivin CM, Crabtree NJ: Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child 2000, 83:143\u2013145.","journal-title":"Arch Dis Child"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","volume":"76","author":"C Brumsen","year":"1997","unstructured":"Brumsen C, Hamdy NA, Papapoulos SE: Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997, 76:266\u2013283.","journal-title":"Medicine (Baltimore)"},{"key":"11_CR49","first-page":"887","volume":"16","author":"LM Gandrud","year":"2003","unstructured":"Gandrud LM, Cheung JC, Daniels MW, Bachrach LK: Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocinol Metab 2003, 16:887\u2013892.","journal-title":"J Pediatr Endocinol Metab"},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1067\/mpd.2003.137","volume":"142","author":"J Steelman","year":"2003","unstructured":"Steelman J, Zeitler P: Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 2003, 142:417\u2013423.","journal-title":"J Pediatr"},{"key":"11_CR51","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1020103901969","volume":"25","author":"S Kanumakala","year":"2002","unstructured":"Kanumakala S, Boneh A, Zacharin M: Pamidronate treatment improves bone mineral density in children with Menkes disease. J Inherit Metab Dis 2002, 25:391\u2013398.","journal-title":"J Inherit Metab Dis"},{"key":"11_CR52","first-page":"2068","volume":"20","author":"FH Glorieux","year":"2003","unstructured":"Glorieux FH, Rauch F, Shapiro JR: Bisphosphonates in children with bone diseases. N Engl J Med 2003, 20:2068\u20132071. The authors most experienced in the use of bisphosphonates in pediatric disorders, especially osteogenesis imperfecta.","journal-title":"N Engl J Med"},{"key":"11_CR53","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S8756-3282(02)00812-8","volume":"31","author":"M Varenna","year":"2002","unstructured":"Varenna M, Zucchi F, Binelli L, et al.:Intravenous pamidronate in the treatment of transient osteoporosis of the hip. Bone 2002, 31:96\u2013101.","journal-title":"Bone"},{"key":"11_CR54","first-page":"107","volume":"21","author":"D Schapira","year":"2003","unstructured":"Schapira D, Braun Moscovici Y, Gutierrez G, Nahir AM:Severe transient osteoporosis of the hip during pregnancy. Successful treatment with intravenous bisphosphonates. Clin Exp Rheumatol 2003, 21:107\u2013110.","journal-title":"Clin Exp Rheumatol"},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0169-6009(91)90129-N","volume":"15","author":"M Passeri","year":"1991","unstructured":"Passeri M, Baroni MC, Pedrazzoni M, et al.:Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991, 15:237\u2013247.","journal-title":"Bone Miner"},{"key":"11_CR56","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","volume":"12","author":"SA Khan","year":"1997","unstructured":"Khan SA, Kanis JA, Vasikaran S, et al.:Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12:1700\u20131707.","journal-title":"J Bone Miner Res"},{"key":"11_CR57","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","volume":"103","author":"D Thiebaud","year":"1997","unstructured":"Thiebaud D, Burckhardt P, Kriegbaum H, et al.:Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997, 103:298\u2013307.","journal-title":"Am J Med"},{"key":"11_CR58","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"D Black","year":"2000","unstructured":"Black D, Thompson DE, Bauer DC, et al.:Fracture risk reduction with alendronate in women with osteoporosis. FIT Research Group. J Clin Endrocrinol Metab 2000, 85:4118\u20134124.","journal-title":"J Clin Endrocrinol Metab"},{"key":"11_CR59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MF McClung","year":"2001","unstructured":"McClung MF, Geusens P, Miller PD, et al.:Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Study Group. N Engl J Med 2001, 344:333\u2013340.","journal-title":"N Engl J Med"},{"key":"11_CR60","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"JD Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber H, et al.:Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a longterm comparative study. Osteoporos Int 2003, 14:801\u2013807.","journal-title":"Osteoporos Int"},{"key":"11_CR61","doi-asserted-by":"crossref","first-page":"81S","DOI":"10.1016\/S8756-3282(99)00071-X","volume":"24","author":"H Buckler","year":"1999","unstructured":"Buckler H, Fraser W, Hosking D, et al.:Single infusion of zoledronate in Paget\u2019s disease of bone: a placebocontrolled, dose-ranging study. Bone 1999, 24:81S-85S.","journal-title":"Bone"},{"key":"11_CR62","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, et al.:Intravenous zoledron acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653\u2013661. This is the best current information about a drug that may permit a once-a-year intravenous dose.","journal-title":"N Engl J Med"},{"key":"11_CR63","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jbmr.5650100505","volume":"10","author":"P Filipponi","year":"1995","unstructured":"Filipponi P, Pedetti M, Fedeli L, et al.: Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995, 10:697\u2013703.","journal-title":"J Bone Miner Res"},{"key":"11_CR64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1359\/jbmr.1997.12.1.103","volume":"12","author":"JE Heikkinen","year":"1997","unstructured":"Heikkinen JE, Selander KS, Laitinen K, et al.:Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res 1997, 12:103\u2013110.","journal-title":"J Bone Miner Res"},{"key":"11_CR65","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ajcn\/76.2.482","volume":"76","author":"KV Haderslev","year":"2002","unstructured":"Haderslev KV, Tjellesen L, Sorensen HA, Staun M: Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition. Am J Clin Nutr 2002, 76:482\u2013488.","journal-title":"Am J Clin Nutr"},{"key":"11_CR66","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S8756-3282(03)00084-X","volume":"33","author":"V Braga","year":"2003","unstructured":"Braga V, Gatti D, Colapietro F, et al.:Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone 2003, 33:342\u2013345.","journal-title":"Bone"},{"key":"11_CR67","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1359\/jbmr.2003.18.12.2083","volume":"18","author":"S Epstein","year":"2003","unstructured":"Epstein S, Inzerillo A, Caminis J, Zaidi M: Disorders associated with acute rapid and severe bone loss. J Bone Miner Res 2003, 18:2083\u20132094.","journal-title":"J Bone Miner Res"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-004-0011-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-004-0011-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-004-0011-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:31:51Z","timestamp":1559421111000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-004-0011-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11914-004-0011-5","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}